U.S. markets open in 9 minutes
  • S&P Futures

    -2.75 (-0.08%)
  • Dow Futures

    -52.00 (-0.18%)
  • Nasdaq Futures

    -22.25 (-0.20%)
  • Russell 2000 Futures

    -1.10 (-0.07%)
  • Crude Oil

    -0.98 (-1.21%)
  • Gold

    +3.00 (+0.18%)
  • Silver

    +0.17 (+0.90%)

    -0.0081 (-0.8277%)
  • 10-Yr Bond

    -0.0330 (-0.88%)
  • Vix

    +1.50 (+4.97%)

    -0.0065 (-0.5872%)

    +0.1790 (+0.1239%)

    +7.20 (+0.04%)
  • CMC Crypto 200

    -4.87 (-1.09%)
  • FTSE 100

    -11.37 (-0.17%)
  • Nikkei 225

    -484.84 (-1.83%)

NurExone Announces Sponsorship and Participation in Gordon Research's 2022 Extracellular Vesicles Conference in Maine, U.S.

·4 min read

Calgary, Alberta--(Newsfile Corp. - July 25, 2022) - NurExone Biologic Inc. (TSXV: NRX) ("NurExone" or the "Company"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal injuries and other Central Nervous System ("CNS") indications, is pleased to announce that it will showcase a poster presentation at the prestigious "Understanding Extracellular Vesicle Biogenesis and Composition for Detection and Treatment of Diseases" conference, hosted by Gordon Research Conference's ("GRC") in Newry, Maine, U.S.

The goal of this conference is to dive into the rapidly growing space of extracellular vesicles and extracellular RNA while bringing in a variety of clinical investigators who are experts in the field. The conference, which commenced on July 24, 2022 and will end on July 29, 2022, will explore the impact that extracellular vesicles (EVs) have on maintaining health, tissue regeneration and more.

NurExone is one of the sponsors of the conference and will set up an in-depth poster presentation detailing its revolutionary ExoPTEN technology and the role it plays in spinal cord regeneration. The presentation covers the science behind exosomes, offers several proofs-of-concept, and demonstrates how the intranasal treatment leads to locomotor, sensory, and bladder recovery.

"GRC offers a distinguished international forum for the latest scientific developments and we are excited to be included in the 2022 Extracellular Vesicles Conference to showcase our innovative exosome-based technology," said Dr. Lior Shaltiel, CEO of NurExone. "The conference will provide us with the opportunity to raise awareness about the promise of nanocarriers for drug delivery and targeted therapy, in front of an international audience consisting of renowned scientists and experts in the field of extracellular vesicles."

The conference is being held in Maine at the Grand Summit Hotel at Sunday River.

About NurExone

NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries. The Company's ExoTherapy will use proprietary exosomes (membrane-bound extracellular vesicles) as biologically-guided nanocarriers to deliver specialized therapeutic compounds to target anatomies. The therapeutic compounds promote a biochemical environment that induces a healing process at the target location. ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone is translating the treatment to humans, and the Company holds an exclusive worldwide license from the Technion for the development and commercialization of the exosome technology.

For more information, please contact:

Dr. Lior Shaltiel
Chief Executive Officer and Director

Investor Relations
+1 905-347-5569


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.


This press release contains certain forward-looking statements, including statements about the Company's future plans, market size and growth, research and product development, the potential to treat SCI using the Company's products, intellectual property protection and potential future collaborations and execution on its current growth initiatives. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof.

Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company's early stage of development, lack of revenues to date, government regulation, market acceptance for its products, rapid technological change, dependence on key personnel, protection of the Company's intellectual property and dependence on the Company's strategic partners. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/131800